BioAtla

BCAB

Market cap $40.8M

Overview Fund Activity

0.6949 USD

-0.0800

10.32%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

0.6901

-0.0048

0.69%

1 day

-10.32%

5 days

12.08%

1 month

88.99%

3 months

73.72%

6 months

92.76%

Year to date

13.18%

1 year

-58.64%

5 years

-97.76%

10 years

-97.76%

About: BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Employees: 61

Healthcare Biotechnology

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

10% more capital invested

Capital invested by funds: $4.76M [Q1] → $5.22M (+$458K) [Q2]

1.03% less ownership

Funds ownership: 23.57% [Q1] → 22.54% (-1.03%) [Q2]

7% less funds holding

Funds holding: 42 [Q1] → 39 (-3) [Q2]

27% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 11

33% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 9

See Fund Rankings

Financial journalist opinion

Neutral

GlobeNewsWire

7 days ago

BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA

FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approval Company continues preparations for enabling initiation of the Phase 3 study with the goal of advancing the study with a strategic partner early next year Company maintains previous guidance for completion of a strategic partnership with one of our advanced clinical assets this year SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its proprietary CAB platform for the treatment of solid tumors, today announced outcomes from its Type B meeting with the United States Food and Drug Administration (FDA).

Neutral

Seeking Alpha

1 month ago

BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript

BioAtla, Inc. (NASDAQ:BCAB ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 AM ET Company Participants Eric L. Sievers - Chief Medical Officer Jay M.

Neutral

The Motley Fool

1 month ago

BioAtla (BCAB) Q2 Loss Narrows 27%

Neutral

GlobeNewsWire

1 month ago

BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

CAB-EpCAM x CAB-CD3 bispecific T-cell engager (TCE) (BA3182) Phase 1 dose-escalation study ongoing, currently dosing 1.2 mg cohort; Phase 1 data readout expected 2H 2025 Fast Track Designated Ozuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study ongoing; meeting planned with U.S. Food & Drug Administration (FDA) in 3Q 2025 to discuss proposed Phase 3 study design Company is advancing partnering discussions and remains confident in our goal to close at least one transaction in 2025 Management to host conference call and webcast today at 4:30 PM Eastern Time SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its proprietary CAB platform for the treatment of solid tumors, today announced its financial results for the second quarter ended June 30, 2025 and provided highlights on its clinical programs. “We continue to be encouraged by the performance of our dual CAB EpCAM x CD3 bispecific TCE, BA3182, in Phase 1 and remain on track for an updated Phase 1 data readout later this year,” said Jay M.

Neutral

GlobeNewsWire

1 month ago

BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, August 7, 2025 at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2025 and provide business highlights.

Neutral

GlobeNewsWire

2 months ago

BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting

SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company” or “BioAtla”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced an oral presentation at the upcoming 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting to be held in Hong Kong Sar, China from July 18–20, 2025. Oral Presentation Details: Title: First-in-human phase I study of a dual-Conditionally Active Biologic (CAB) EpCAM x CD3 bispecific T-cell engager (TCE), BA3182, in patients with treatment refractory metastatic adenocarcinoma Authors: Jennifer B.

Neutral

GlobeNewsWire

2 months ago

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress

Adverse events were generally low-grade, transient, and readily manageable Achieved preliminary evidence of prolonged tumor control and tumor reductions in heavily pretreated adenocarcinoma patients Dose escalation now continuing at 1.2 mg weekly by subcutaneous flat dosing SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company” or “BioAtla”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today presented first-in-human data in a poster titled “Preliminary Results from a First-in-Human Phase 1 Study of a Dual-Conditionally Binding CAB-EpCAM x CAB-CD3 Bispecific T-cell Engager, BA3182, in Patients with Treatment Refractory Metastatic Adenocarcinoma” at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress being held in Barcelona, Spain from July 2–5, 2025. In the ongoing Phase 1 dose-escalation clinical trial, as of June 20, 2025, 39 patients with heavily pretreated metastatic adenocarcinoma were dosed in cohorts ranging from 0.0026 mg to 0.6 mg BA3182 QW, with either 0, 1, or 2 priming dose(s) delivered four to seven days prior to treatment dosing.

$BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress$